header logo image


Page 185«..1020..184185186187..190200..»

Maryland Cancer Moonshot Initiative Promises $216 Million for Research and Treatment Conduit Street – Conduit Street

April 2nd, 2022 1:48 am

Maryland will be committing $216 million to expand and accelerate cancer detection, screening, prevention, treatment, and research through Governor Larry Hogans recently announced Maryland Cancer Moonshot Initiative.

Governor Larry Hogan explained the personal significance of the initiative in a press release:

The reality is that cancer is a disease that has touched nearly every one of us, through family or loved ones, saidGovernor Hogan. On the day I found out I was cancer-free, I pledged that as long as I am governor and long after, I will stand with all those who are fighting this terrible disease. That is why today, I am announcing the Maryland Cancer Moonshot, to dramatically accelerate all of our efforts to detect, prevent, treat, and find a cure for cancer, so that more lives can be saved. This is a watershed moment in the fight against cancer in our state and the region.

The substantial initial investment is a part of Governor Hogans fifth supplemental budget and will include funding for the following:

Greenebaum Cancer Center:$100 million for the expansion of the University of Maryland Medical Systems Greenebaum Comprehensive Cancer Center (UMGCCC) in downtown Baltimore to providestate-of-the-art inpatient and outpatient cancer services. UMGCCC, which is a National Cancer Institute-designated comprehensive cancer center, treats approximately 3,000 new patients annually. This investment completes the states commitment to the project.

Prince Georges Comprehensive Cancer Center:$67 million to fully fund the construction of a new comprehensive cancer center on the campus of the newUniversity of Maryland Capitol Region Medical Centerin Largo. This best-in-class cancer will be a premiere clinical and research center to serve the residents of Prince Georges County and the region. The state funding includes a $27 million commitment by the governor, a $13.5 million commitment by the Maryland Senate and a $26.5 million commitment by the Maryland House of Delegates.

Cancer Research:$25 million for the University of Maryland School of Medicine and Johns Hopkins University to accelerate cancer research projects.

Pediatric Cancer Research:$1 million to support expanding pediatric cancer research at the University of Maryland School of Medicine.

Stem Cell Research Fund:$20.5 million for the Maryland Stem Cell Research Fund (MSCRF) to catalyze investment in regenerative medicine projects to develop novel cures and groundbreaking treatments for prevalent cancers.

Maryland Tech Council:$2.5 million for the BioHub Maryland Initiative to expand the states life sciences and biotechnology research workforce, with a focus on talent development, upskilling opportunities, and outreach to students in underserved communities. Maryland is proud to be home to one of thetop biotech clustersin the United States.

Read the full press release.

Like Loading...

More:
Maryland Cancer Moonshot Initiative Promises $216 Million for Research and Treatment Conduit Street - Conduit Street

Read More...

Medical Technologies Leader Cellmyx Announces US Food and Drug Administration (FDA) 510(k) Clearance for intelliFat BOD (Ref.# K210528) – PR Newswire

April 2nd, 2022 1:48 am

The most advanced, quickest and easiest, single-use kit for macro, micro, and nano fat tissue harvesting, processing, and transfer.

CARLSBAD, Calif., March 29, 2022 /PRNewswire/ -- Cellmyx, the authority on autologous adipose grafting and transfer, and a leader in medical technologies for orthopedic physicians,pain management and regenerative medicine, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for intelliFat BOD (Ref.# K210528). The most advanced, quickest and easiest, single usekit for macro, micro, and nano fat tissue harvesting, processing,and transfer.

U.S. regulators have cleared the way for this groundbreaking new medical appliance and technology for use in orthopedic, plastic, and cosmetic surgery procedures. intelliFat BOD successfully uses a patient's own body fat, clinically referred to as adipose tissue, to aid in patient recovery and healing. In some cases, intelliFat BOD is used in conjunction with traditional orthopedic surgery to further advance patient outcomes. intelliFat BOD is particularly attractive to physicians because it's compliant with the latest FDA guidelines, preserving cellular and tissue micro-architecture of adipose, eliminating residual oil emulsion and blood, thereby providing a tissue byproduct that is minimally manipulated in accordance with FDA guidelines for Human Cell and Tissue Products.

Kits are sterile, and disposable, and contain a full suite of proprietary and stand-alone components toharvest, process, and transfer autologous adipose tissue for use as an alternative, and/or as an adjunct, to surgery for filling soft tissue defects and promoting healing in orthopedics, plastic, and cosmetic surgery, and a multitude of other surgical procedures and specialties.

Physicians feel empowered. They have the assets they need right at their fingertips to perform this revolutionary procedure without incising, stitching, or scarring the patient. intelliFat BOD streamlines procedure times to under 30 minutes with its patented and unparalleled harvesting, processing, and transfer system. Patients experience no discomfort or downtime during or post-procedure and may return to normal social activities immediately with clearance from their provider.

According to Associate Clinical Professor of Medicine, University of Connecticut School of Medicine, Fellow of the American Osteopathic Academy of Sports Medicine, and Board Certified in Sports Medicine & Regenerative Medicine Dr. Paul D. Tortland, D.O. FAOASM, RSMK:

"I began performing autologous fat derived treatments for orthopedic regenerative medicine in 2009, the first physician in New England, and among the earliest in the country. Over the years I've trialed most commercially available systems to harvest and prepare adipose for injection. I have found these systems are cumbersome to use, time-consuming, or produce suboptimal product for injection.But with intelliFat BODCellmyx hit the mark. Their kit is elegantly simple, fast and easy to use, and produces a superlative final product that's easy to inject. Most importantly, I'm seeing outstanding clinical results."

The intelliFat510(k) specifically includes procedures for neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, plastic, cosmetic, and reconstructive surgery, general surgery, orthopedic surgery, gynecological surgery, laparoscopic surgery, arthroscopic surgery, and thoracic surgery.

About Cellmyx:

Millennium Medical Technologies dba Cellmyx is a U.S. Food and Drug Administration (FDA) registered manufacturer committed to providing comprehensive solutions and support for harvesting, isolation, and deployment of PHSA 361 compliant tissue and cells. Cellmyx is committed to advancing the art of cosmetic surgery and regenerative medicine and continues to explore and develop novel concepts to enhance their proprietary product portfolio bringing physicians the most advanced technology in adipose tissue transfer.

Media Contact:

Terence Kazlow, Director of Sales and Marketing Greg Miles, CEO and Founder 949-215-8560 [emailprotected]

SOURCE Cellmyx

View post:
Medical Technologies Leader Cellmyx Announces US Food and Drug Administration (FDA) 510(k) Clearance for intelliFat BOD (Ref.# K210528) - PR Newswire

Read More...

Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference – GlobeNewswire

April 2nd, 2022 1:48 am

SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

The Companys webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website at http://www.aziyo.com. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at http://www.lythampartners.com/spring2022invreg.

About Aziyo Biologics

Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit http://www.Aziyo.com.

Investors:Leigh Salvo Gilmartin Groupinvestors@aziyo.com

Read the original here:
Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference - GlobeNewswire

Read More...

CollPlant to trial 3D bioprinted breast implants in breakthrough animal study – 3D Printing Industry

April 2nd, 2022 1:48 am

Regenerative medicine specialist CollPlant (NASDAQ: CLGN) has revealed that the 3D bioprinted breast tissues its developing are set to enter animal trials in the very near future.

Alongside the release of its FY 2021 results, which show that it generated $15.6 million in revenue, 155.7% more than the $6.1 million it reported in FY 2020, CollPlant announced that its bioprinted implants will enter in-vivo testing from Q2 2022.

Currently being developed with BICO firm CELLINK, the grafts are designed to gradually degrade and be replaced by native tissues, in a safer alternative to breast augmentation procedures. With further R&D, the companies believe their approach could be deployed in up to 2.2 million surgeries, enabling them to address a market worth an estimated $2.8 billion.

In the year ahead, we anticipate reaching development milestones for some of our leading programs, including the start of a large animal study for our 3D bioprinted regenerative breast implant program, said Yehiel Tal, CEO of CollPlant. We are also making continued progress with the development of bio-inks for 3D bioprinting applications, and with development of a photocurable dermal filler.

CollPlants FY 2021 financials

Although CollPlant hasnt provided a division-by-division breakdown of its annual revenue, its clear from what has been revealed, that its rate of growth is beginning to accelerate. In large part, the firms rapid rise in revenue last year was down to a $103 million bioprinting contract it signed with AbbVie company Allergan Aesthetics during March 2021.

As part of this agreement, the latter has begun to use CollPlants artificial collagen to create dermal and soft tissue fillers, and it could go on to develop two more products in future. The deal has also seen CollPlant receive an initial $14 million, and while this represented 90% of its FY 2021 revenue, it could gain another $89 million in milestone payments should any of Allergan Aesthetics products make it to market.

In addition to generating more revenue in FY 2021 than FY 2020, the company improved its profitability as well, raising its gross profit from $3.1 million to $13.6 million. This was primarily due to the fact that over this period, its cost of revenue fell from $3 million to $2 million, owing to expenses related to royalties, bio-ink and rhCollagen sales, and the ending of its deal with United Therapeutics in FY 2020.

Thanks largely to a registered direct offering in February 2021, which saw it raise $31.8 million in net proceeds and $6 million from the exercise of warrants, CollPlant was able to attract $38.8 million in financing across last year. As it happens, some $31.6 million of this funding was deployed immediately in short-term cash deposits, the likes of which generated up to $172,000 for the firm in FY 2020.

CollPlants breast implant trials

Since announcing the creation of its first regenerative breast implants in 2019, the firm has steadily sought to improve their clinical and commercial viability. The tissues themselves are made from patient fat cells and ECM components, as well as rhCollagen, CollPlants tobacco plant-grown alternative to animal or cadaver-sourced collagen.

In theory, once these grafts are injected into patients tissues, they foster the regeneration of native cells before slowly degrading, leaving behind no foreign contaminants. CollPlant says this procedure could offer a revolutionary alternative to silicone implants or fat transfer operations which come with a risk of adverse events, but they arent yet ready for market, and continue to undergo clinical trials.

One way the company has sought to accelerate the development of its bioprinted breast implants is via its recently-established partnership with CELLINK. When the collaboration was announced last month, CollPlant said that CELLINKs high-throughput bioprinters and expertise could enable it to overcome the hurdles facing its implants scalability.

That being said, the firm has also worked with 3D Systems before to develop breast reconstruction treatments for cancer survivors, and its possible that its current work will allow it to build on some of the findings it made as part of this project too.

In the case of its newly-announced trials, CollPlant has let little slip about their exact set up, but theyre understood to offer an opportunity to put its learnings from preclinical studies into practice, while taking a significant step forward in its breast implants R&D, in that their viability will now be tested in-vivo at scale.

Advances in breast implant bioprinting

Even though 3D bioprinting itself remains an emerging technology, a significant amount of progress has already been made in using it to produce viable breast implants. Earlier this year, Healshape raised $6.8 million towards the R&D of its patient-specific breast tissues, designed to treat those who have undergone a mastectomy.

In the past, Plcoskin has also announced plans to work with Yonsei University and LipoCoat with the aim of coming up with a novel 3D printed breast implant. In essence, the project was set up to combine LipoCoats lipid film coating technology and Plcoskins PCL-collagen coating approach, as a means of developing a uniquely-glazed graft that offers a reduced risk of infection or rejection.

Elsewhere, similar technologies are being developed to create all sorts of other tissues as well, ranging from the 3D bioprinted human tescticle cells produced at the University of British Columbia, to the bioprinted liver tissues of T&R Biofab.

To stay up to date with the latest 3D printing news, dont forget to subscribe to the 3D Printing Industry newsletter or follow us on Twitter or liking our page on Facebook.

For a deeper dive into additive manufacturing, you can now subscribe to our Youtube channel, featuring discussion, debriefs, and shots of 3D printing in-action.

Are you looking for a job in the additive manufacturing industry? Visit 3D Printing Jobs for a selection of roles in the industry.

Featured image shows a 3D bioprinted breast implant produced by CollPlant. Photo by Valerie Arad, CollPlant.

Go here to read the rest:
CollPlant to trial 3D bioprinted breast implants in breakthrough animal study - 3D Printing Industry

Read More...

Researchers Receive $2.5 Million Grant to Study Appendiceal Cancer – Newswise

April 2nd, 2022 1:48 am

Newswise WINSTON-SALEM, N.C. March 31, 2022 Cancer of the appendix is rare, affecting only 1 in 100,000 people in the United States annually. However, because its so rare, theres limited research to help guide treatment decisions. But now, researchers at Atrium Health Wake Forest Baptists NCI-designated Comprehensive Cancer Center hope to change that with support from a $2.5 million grant from the National Cancer Institute.

Because the appendix is part of the gastrointestinal system, appendiceal cancers have traditionally been treated in the same way as colon cancer, said Lance Miller, associate professor of cancer biology at Wake Forest School of Medicine and co-principal investigator of the study. However, were learning that these cancers are molecularly very different. By increasing our molecular understanding of appendiceal cancer, we hope to have greater insight on how best to treat, which will lead to better outcomes.

According to Miller, appendiceal cancer is often diagnosed at late stages when it has already spread throughout the peritoneal cavity, the space within the abdomen that contains the stomach, liver and intestines. As a result, current treatment options are limited.

One treatment forpatients withappendiceal tumors with spread to the peritoneal cavityis cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). TheCRS/HIPECprocedureinvolvessurgicallyremoving the cancerous tumors followed by the administration of heated chemotherapy directly into the abdomen to kill any residual cancer cells.

Wake Forest Baptist Medical Center was among the first hospitals in the U.S. to offer the procedure in 1991. The program is led by Dr. Edward Levine, professor of surgical oncology at Wake Forest School of Medicine and co-investigator of this study.

A major challenge is that some patients respond well to CRS/HIPEC, and some do not, said Dr. Konstantinos Votanopoulos, professor of surgery and director of the Wake Forest Organoid Research Center (WFORCE), a joint effort between the Wake Forest Baptist Comprehensive Cancer Center and the Wake Forest Institute for Regenerative Medicine (WFIRM) to tailor personalized therapy for patients. CRS/HIPEC is an aggressive, yet often effective, treatment in prolonging survival, but we dont know how patients will respond ahead of time.

Votanopoulos, who is also a co-principal investigator of the study, said the grant will support three objectives. One, researchers will build on previous research to develop a genetic test that will help identify patients who will benefit from CRS/HIPEC. Two, researchers will study gene expression patterns of high-grade tumors and how they impact survival. And three, the grant will support the use of patient-derived tumor organoids to study how mutations in the cancer might make a tumor more sensitive or resistant to certain chemotherapy drugs.

The creation of an organoid begins with a tissue biopsy of a tumor. Cells from this biopsy are then used to grow three-dimensional, patient-specific tumor organoids in the lab. By exposing the organoids to various chemotherapy drugs and observing their response, scientists can possibly predict how a patient will respond to treatment.

This research has the potential to create new possibilities for personalized medicine in the treatment of appendiceal cancer, Miller said.

Read more:
Researchers Receive $2.5 Million Grant to Study Appendiceal Cancer - Newswise

Read More...

Company Founded by Harvard Researchers to Launch Alternative Meat Product | News – Harvard Crimson

April 2nd, 2022 1:48 am

Tender Foods, a food technology startup co-founded by four Harvard-affiliated researchers that produces alternative meats, is preparing for a product launch later this year.

The company, which produces plant-based meat spun from liquid polymers, is one of 27 startups launched in fiscal year 2021 to commercialize innovations from Harvard research labs. Tender Foods specializes in products that have a unique texture, structure, and ultimately taste, according to its founders.

A lot of the stuff that tries to mimic meat is textured, but its not fibrous, so its aligned and its a block of stuff, but its not individual fibers, said Luke A. MacQueen, one of the startups co-founders and a Harvard postdoctoral researcher in Bioengineering.

The Tender Foods products will better mimic the texture of real meat, MacQueen said.

MacQueen co-founded the company alongside three other Harvard affiliates: Bioengineering and Applied Physics professor Kevin K. Kit Parker, Grant M. Gonzalez 13, and SEAS researcher Christophe Chantre.

The fibers in Tender Foods meat are made using technology developed by Parker and his colleagues. The research group studied rotary jet-spinning, which uses centrifugal force to elongate liquid polymers into fibers. MacQueen likened the device to a cotton candy machine that works with different kinds of proteins.

The technology was initially used for various other purposes, including organ regeneration: in 2017, the researchers managed to spin nanofibers into biocompatible heart valves. Two years later, they showed the same could be done with gelatin scaffolds to hold animal muscle cells.

Every lesson learned from building tissues for regenerative medicine was applicable to building tissue to eat, Parker wrote in an email.

MacQueen said he is excited to see the variety of meats that might emerge from the startups technology.

When those fibers are spun and collected into a system, they can be tailored to be like the meat products people enjoy, whether they be as simple as a chicken breast or much more complicated layered structures, he said. Those can all be made in an artisanal way, starting with this very basic building block.

The research received funding from the Harvard Office of Technology Development and Harvards Wyss Institute for Biologically Inspired Engineering.

The first efforts to patent discoveries from my lab pertaining to meat were shot down by OTD around 2006, Parker wrote. We kept pushing.

MacQueen said he is excited to introduce Tender Foods products to the public.

As a young startup, weve had to kind of stay under the radar a little bit, but theres good things coming down the road, he said.

I ate some this morning, Parker added in an email. It was delicious.

Staff writer Felicia He can be reached at felicia.he@thecrimson.com.

Staff writer James R. Jolin can be reached at james.jolin@thecrimson.com.

Link:
Company Founded by Harvard Researchers to Launch Alternative Meat Product | News - Harvard Crimson

Read More...

Stem cell therapy shows promise in aiding equine wound healing – Horsetalk.co.nz – Horsetalk

April 2nd, 2022 1:47 am

WCVM PhD student Dr Suzanne Mund. Rigel Smith

A team of researchers at the Western College of Veterinary Medicine (WCVM) in Saskatchewan has published the first equine study to demonstrate changes in wound healing following stem cell therapy.

The findings of the study, which received funding from the Mark and Pat DuMont Equine Orthopedic Fund and the WCVMs Townsend Equine Health Research Fund (TEHRF), were recently published online in Cells, an international open-access journal.

Team members include PhD student Dr Suzanne Mund along with WCVM faculty members Drs Daniel MacPhee, John Campbell, Ali Honaramooz, Bruce Wobeser and Spencer Barber.

The Canadian researchers used intravenous (IV) treatments of multipotent mesenchymal stromal cells (MSCs) that were extracted from other horses. These stem cells have potential for improving wound healing because they can alter the bodys inflammatory response, which is involved in healing. They can also influence other local cells to produce growth factors that could enhance the speed and quality of wound healing.

MSC therapy is a promising treatment for limb wounds, a common injury in horses that often develops complications, which can include the production of an excess amount of granulation tissue, commonly known as proud flesh.

There are risks associated with IV administration of MSC, and so far, the therapys effectiveness in improving cutaneous wound healing is unknown.

The WCVM research team was successful in administering the highest dose of MSCs ever administered to horses enrolled in the study (using any type of delivery). Contrary to the teams hypothesis, the treated horses did not experience accelerated wound closure or improved histologic healing. However, the horses healed wounds did have smaller immature scar sizes, which may signal a better repair in terms of cosmetics and function.

The stem cell therapy also appeared to alter the cytokine profile within the horses wounds. Cytokines are small proteins that play a role in controlling the growth and activity of other immune system cells and blood cells. After treatment, there was less expression of all measured cytokine types except for antifibrotic mediators.

This finding is contrary to researchers understanding that more acute inflammation followed by rapid resolution improves limb wound healing.

Another concern was that several of the horses in the treatment group temporarily developed minor reactions after receiving stem cell therapy. Since one horse in the control group also experienced similar transient reactions, the cause may be related to the cell suspension solution used or to other external factors rather than to the cells themselves.

While MSC intravenous therapy has the potential to decrease the size of limb wounds in horses, researchers need to dofurther studies before this therapy can be recommended as an effective wound healing tool for veterinarians in the field. More work also needs to be done to understand the clinical relevance of adverse reactions that were observed in the studys horses.

Reprinted with permission from the Western College of Veterinary Medicines Townsend Equine Health Research Fund.

Go here to see the original:
Stem cell therapy shows promise in aiding equine wound healing - Horsetalk.co.nz - Horsetalk

Read More...

Rheumatoid Arthritis Stem Cell Therapy Market Assessment, With Major Top Companies Analysis, Geographic Analysis, Growing Opportunities Data By…

April 2nd, 2022 1:47 am

Prophecy Market Research delivered a business report on the Rheumatoid Arthritis Stem Cell Therapy which is the best creation of trust and skill. The report is a top to bottom assessment of the different attributes and future development possibilities during the figure time frame. To uncover every doable way, our examiners applied different strategies. It contains every one of the overall significant organizations to help our clients in understanding their thorough strategies and cutthroat climate.

The noticeable players in the worldwide Rheumatoid Arthritis Stem Cell Therapy are

Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others

Our investigator have partitioned the report into segments so you might become familiar with the overall market undiscovered possibility in every one.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4815

The market elements are analyzed inside and out in the outline segment. This part is an unquestionable requirement perused for anybody settling on information driven choices. It talks about how Rheumatoid Arthritis Stem Cell Therapy functions, as well as market size and volume. The report is coordinated in straightforward organizations and incorporates outlines, tables, and charts to inspect the information and uncover the secret example in the numbers. Besides, the report incorporates verifiable deals and income data as well as guage designs for the following not many years.

The development and limiting elements are given their own fragment to help our clients in observing the Rheumatoid Arthritis Stem Cell Therapy touch spots and problem areas. The ends attracted this part depend on trustworthy and more significant position sources. Our specialists have utilized an assortment of market projection ways to deal with furnish our clients with reliable outcomes.

The Rheumatoid Arthritis Stem Cell Therapy is isolated into different groupings in the division segment. The fragment is an inside and out assessment of every classification, which is grouped by its qualities and expansiveness. Weve recorded every one of the measurements along with subjective clarifications to assist clients with appreciating the expected broadness of each class before very long. To dispose of errors in current realities and discoveries, the report utilizes an assortment of measurable methodologies. Moreover, an assortment of pattern projection approaches are utilized to uncover future development angles and prospects.

By Product Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant and Adipose Tissue Stem Cells)

By End-User (Hospitals, Ambulatory Surgical Centers and Specialty Clinics)

By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others

Promising Regions & Countries Mentioned In The Rheumatoid Arthritis Stem Cell Therapy Report:

The local review area inspects all potential market scenes in specific areas before very long. Its an exhaustive assessment of the Rheumatoid Arthritis Stem Cell Therapy possible districts. The examination additionally remembers a contextual investigation for significant market members to help shoppers distinguish and understand powerful techniques in the overall Rheumatoid Arthritis Stem Cell Therapy , as well as likely boundaries. Our master experts checked the data and endeavored to protect the most ideal degree of exactness.

Segmentation Overview:

By Product Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant and Adipose Tissue Stem Cells)

By End-User (Hospitals, Ambulatory Surgical Centers and Specialty Clinics)

By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/4815

Purposes Behind Buying Rheumatoid Arthritis Stem Cell Therapy Report-

openings both developed and arising regions.

Understanding the tactics that support marketable interest in terms of products, segmentation, and assiduity verticals can help you make better opinions.

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Rheumatoid-Arthritis-Stem-Cell-Therapy-Market-4815

Why Buy From Us?

Prophecy Market Insights is particular statistical surveying, investigation, promoting/business technique, and arrangements that offers vital and strategic help to clients for settling on very much informed business choices and to distinguish and accomplish high-esteem valuable open doors in the objective business region. We likewise assist our clients with tending to business challenges and give the most ideal answers for conquer them and change their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Continue reading here:
Rheumatoid Arthritis Stem Cell Therapy Market Assessment, With Major Top Companies Analysis, Geographic Analysis, Growing Opportunities Data By...

Read More...

Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting – Yahoo…

April 2nd, 2022 1:47 am

Jasper Therapeutics

REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that updated data from the Companys ongoing study of JSP191 as single agent conditioning prior to allogeneic hematopoietic stem cell (HSC) re-transplant in patients with severe combined immunodeficiency (SCID) has been accepted for presentation as a late-breaking poster at the 2022 Clinical Immunology Society (CIS) Annual Meeting, to be held in Charlotte, North Carolina from March 31 to April 3, 2022.

Title: Update: Single-Agent Conditioning with Anti-CD117 Antibody JSP191 Shows Donor Engraftment, Nave Lymphocyte Production, and Clinical Benefit in Patients with Severe Combined Immunodeficiency (SCID)Date and Time: Friday, April 1, 2022, 1:00-2:00 p.m. ET

This updated data indicates that JSP191 at 0.6mg/kg can deplete blood stem cells, leading to long-term donor cell engraftment, immune reconstitution which positively affects the clinical status of SCID patients who suffer from poor T cell and negligible B cell immunity because they failed their first transplant, said Wendy Pang, MD, Ph.D., Senior Vice President of Research and Translational Medicine of Jasper Therapeutics. This population of SCID patients is largely without treatment options and rely on supportive therapies like life long IVIG to provide some level of immune protection. JSP191 based conditioning may provide these patients with the best chance of a safe and successful transplant and reconstituted immune system.

CIS attendees are the primary caregivers for the immune deficient patient population, we are pleased to be able to present this data at the 2022 CIS annual meeting, Ronald Martell, CEO of Jasper. We believe that with our successful clinical efforts, we are one step closer, and uniquely positioned to deliver a targeted non-genotoxic conditioning agent to patients with SCID.

Story continues

About JSP191

JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or genetically modified transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 100 healthy volunteers and patients. Three clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), severe combined immunodeficiency (SCID) and Fanconi anemia are currently enrolling. The Company plans a new study of JSP191 as a second-line therapeutic in lower risk MDS patients in 2022 as well as to a pivotal study in MDS/AML transplant in early 2023. Enrollment in additional studies are planned in patients with sickle cell disease, chronic granulomatous disease and GATA2 MDS who are undergoing hematopoietic cell transplantation.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical mRNA engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) and Jaspers ability to potentially deliver a targeted non-genotoxic conditioning agent to patients with SCID. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jaspers product candidates; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com

Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com

Read this article:
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo...

Read More...

Explained: What is genome editing technology and how is it different from GM technology? – The Indian Express

April 2nd, 2022 1:46 am

On Wednesday, the central government paved the way for easy introduction of genome edited crops. The government has clearly distinguished such crops from genetically modified crops and has prescribed relatively easier norms for their introduction. The Indian Express explains what genome editing is and how it is different from genetically modified crops.

Subscribe Now: Get Express Premium to access the best Election reporting and analysis

A decade ago, scientists in Germany and the US discovered a technique which allowed them to cut DNA strands and edit genes. For agriculture scientists this process allowed them to bring about desired changes in the genome by using site directed nuclease (SDN) or sequence specific nuclease (SSN). Nuclease is an enzyme which cleaves through nucleic acid the building block of genetic material.

Advanced research has allowed scientists to develop the highly effective clustered regularly interspaced palindromic repeat (CRISPR) -associated proteins based systems. This system allows for targeted intervention at the genome sequence. This tool has opened up various possibilities in plant breeding. Using this tool, agricultural scientists can now edit genome to insert specific traits in the gene sequence. Depending on the nature of the edit that is carried out, the process is divided into three categories SDN 1, SDN 2 and SDN 3.

SDN1 introduces changes in the host genomes DNA through small insertions/deletions without introduction of foreign genetic material. In the case of SDN 2, the edit involves using a small DNA template to generate specific changes. Both these processes do not involve alien genetic material and the end result is indistinguishable from conventionally bred crop varieties. On the other hand, SDN3 process involves larger DNA elements or full length genes of foreign origin which makes it similar to Genetically modified organisms (GMO) development.

Genetically modified organisms (GMO) involves modification of the genetic material of the host by introduction of a foreign genetic material. In the case of agriculture, soil bacteria is the best mining source for such genes which are then inserted into the host genome using genetic engineering. For example, in case of cotton, introduction of genes cry1Ac and cry2Ab mined from the soil bacterium Bacillus Thuringiensis (BT) allow the native cotton plant to generate endotoxins to fight pink bollworm naturally. BT Cotton uses this advantage to help farmers naturally fight pink bollworm which is the most common pest for cotton farmers.

The basic difference between genome editing and genetic engineering is that while the former does not involve the introduction of foreign genetic material, the latter does. In the case of agriculture, both the techniques aim to generate variants which are better yielding and more resistant to biotic and abiotic stress. Before the advent of genetic engineering, such variety improvement was done through selective breeding which involved carefully crossing plants with specific traits to produce the desired trait in the offspring. Genetic engineering has not only made this work more accurate but has also allowed scientists to have greater control on trait development.

Across the world, GM crop has been a topic of debate, with many environmentalists opposing it on the grounds of bio safety and incomplete data. In India, the introduction of GM crops is a laborious process which involves multiple levels of checks. The Genetic Engineering Appraisal Committee (GEAC), a high power committee under the Ministry of Environment, Forest and Climate Change, is the regulator for introduction of any GM material and in case of agriculture multiple field trials, data about biosafety and other information is necessary for getting the nod before commercial release of any GM crop. Till date the only crop which has crossed the regulatory red tape is Bt cotton.

Scientists both in India and across the world have been quick to draw the line between GM crops and genome edited crops. The latter, they have pointed out, has no foreign genetic material in them which makes them indistinguishable from traditional hybrids. Globally, European Union countries have bracketed genome edited crops with GM crops. Countries like Argentina, Israel, US, Canada, etc have liberal regulations for genome edited crops.

Last year, a group of eminent agricultural scientists had written to Prime Minister Narendra Modi voicing their concern about what they said was a move to put the issue of genome edited crops to the back burner. Back then, the central government had invited suggestions and objections from states and Union Territories about the issue and put on hold field trials of such crops. The signatories, many of whom were Padma awardees, had categorically said that the variants developed through SDN1 and SDN2 techniques do not have any alien DNA and as such can be treated as other hybrids.

Newsletter | Click to get the days best explainers in your inbox

On Wednesday, the Environment Ministry put a lid to the topic by issuing fresh guidelines. The Wednesdays notification has exempted SDN 1 and SDN 2 genmoe from the same and instead it would rely on reports of Institutional Biosafety Committee to exclude exogenous genetic material.

The institutional biosafety committees are expert committees constituted under the Act to deal with research and release of GM material. Such committees would now be entrusted to certify that the genome edited crop is devoid of any foreign DNA This would be a less cumbersome and time consuming process for commercial release of genome edited crops.

Original post:
Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express

Read More...

San Antonio Zoo In Discussions on Woolly Mammoth Project – iHeart

April 2nd, 2022 1:46 am

San Antonio Zoo is in discussions with Colossal Laboratories & Biosciences on several projects, one of which is the return of the Woolly Mammoth through DNA de-extinction technology. The ultimate goal is for Woolly Mammoths to be re-introduced to the wild to decelerate the melting of arctic permafrost, prevent greenhouse emissions trapped within the permafrost layer, revert now-overshrubbed forest into natural arctic grasslands, and more. San Antonio Zoo could be the first location of this genetically engineered elephant-mammoth hybrid.

One of Colossals main goals is the de-extinction of species. According to leading scientists, on average, 30,000 species are being driven to extinction. That is 6 per hour, 150 per day, and up to 55,000 per year. The United Nations has declared that 1 million plants and animal species are threatened with extinction.

CRISPR, the most advanced, applicable technique in genetic engineering, is an engineered cellular technology used for recognizing and cutting a specific code of DNA inside the nucleus. In mammalian cells, such as an elephant or a Woolly Mammoth, CRISPR works with an enzyme called Cas9 to modify genes. A CRISPR-Cas9 complex will use a single guide RNA from CRISPR to guide and recognize a specific sequence of DNA, where the Cas9 molecule will cleave those strands that are complementary to the CRISPR sequence. This allows for the reinsertion of the laboratory-engineered DNA, giving the ability to insert cold-resistant characteristics into elephant DNA. Ultimately, leading to the de-extinction of the Woolly Mammoth.

Our goal is to have our first calves in the next four to six years, said Austinite tech entrepreneur Ben Lamm, Cofounder of Colossal. This is going to change everything.

There are times when technology and nature collide - however, through DNA work and the de-extinction science behind Colossal, this is a time when nature and humankind will benefit, said Tim Morrow, President & CEO of San Antonio Zoo. Through this science, we hope to find a vaccine for EEHV, a virus that strikes elephants, and restore a balance to nature by saving and de-extincting species on the brink.

Prior to reintroduction into the wild, San Antonio Zoo is positioning itself to utilize zoo grounds on the west side of Highway 281 with a landbridge, similar to the recently opened Hardberger Park Land Bridge, to allow the Woolly Mammoths to have access to large acreage as well as viewability for guests in the current elephant habitat.

According to Colossal, genetic engineering is used to help humanity advance treatments for genetic disorders, gene therapies, DNA fingerprinting, vaccines, and pharmaceutical products. Additional applications include sustainable plant and animal food production, diagnosing diseases and conditions, medical treatment improvement, and producing vaccines and other useful drugs. Genetic engineering applications for animals include advancing human health, enhancing food production, reducing environmental impact, optimizing animal health and welfare, and producing cutting-edge industrial applications.

Other world-bettering uses include eradicating malaria, organ donorship, and of course, the slowing of and reversal of the extinction of a species. To learn more about Association of Zoos & Aquariums program Saving Animals From Extinction (SAFE) visit: http://www.aza.org/safe-species

To learn more about International Elephant Foundation programs visit: https://elephantconservation.org/

Colossal Background presented by CNN: https://www.cnn.com/2021/09/13/world/woolly-mammoth-resurrect-deextinction-scn/index.html

Visit: San Antonio Zoo

More here:
San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart

Read More...

Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference – Yahoo…

April 2nd, 2022 1:46 am

CRISPR and molecular engineering company scheduled to join panel discussing gene editing innovations

ALAMEDA, Calif., April 01, 2022--(BUSINESS WIRE)--Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the Goldman Sachs The New Guard: Privates Leading The Disruption In Healthcare conference.

Benjamin Oakes, CEO and co-founder of Scribe Therapeutics, will join the "Gene Editing: Moving from Molecular Scissors to Pencils" panel on Thursday, April 7, 2022 at 10 a.m. ET in New York, NY.

About Scribe Therapeutics

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribes mission to engineer the future of genetic medicine, visit http://www.scribetx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005137/en/

Contacts

Thermal for Scribe TherapeuticsKaustuva Dasmedia@scribetx.com

Excerpt from:
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo...

Read More...

Xenotransplantation trials will require adjusting expectations, experts say – STAT

April 2nd, 2022 1:46 am

On the heels of some important firsts this past year, xenotransplantation grafting animal organs into humans is on the cusp of crossing over into new territory: human trials.

In January, University of Maryland surgeons transplanted a pig heart into a 57-year-old man, who survived two months. And last fall, New York University doctors implanted pig kidneys into recently deceased individuals to show there wouldnt be immediate rejection of the organs. As exciting as these procedures were for researchers who have been trying to make xenotransplantation a reality, they highlighted the slow pace of clinical development, which has been stalled in primate studies for decades.

In order to move from preclinical work in monkeys to FDA-approved clinical trials in people, the transplant community will need to adjust its definition of success, Robert Montgomery, director of the NYU Langone Transplant Institute, said Thursday at the 2022 STAT Breakthrough Science Summit in New York City.

advertisement

Standard human-to-human organ transplants have remarkable success rates for some organs. A year after a kidney transplant, 95% of recipients are still alive, said Montgomery, who performed the pig-to-human kidney procedures last year. Xenotransplantation will necessarily take time to get to that same level, he said. Were going to have the equivalent of an Apollo One disaster.

But the current success rates are an unfair standard for xenotransplantation, he said, because they ignore the thousands who die of organ failure every year without being able to get a transplant. I think the reason weve been in the non-human primate model for 30 to 40 years is just that. That the step into humans has been so encumbered with the idea that you have to get equipoise or some type of an equivalent outcome, he said. But to me its apples to oranges. What were really talking about is the organ shortage.

advertisement

Were talking about the half of people who get listed [for a transplant] who die thats what we should be comparing this to, not to the success of the half that are lucky and get opportunity like myself and my brother to live.

Montgomery himself had to be resuscitated from seven episodes of cardiac arrest before he made it on the list to await a donor heart. He eventually received a heart transplant, as did one of his brothers, but he said the risk-reward calculation for venturing into human xenotransplant trials should include patients who died at every step in the process.

Every patient that dies on the waitlist, we should be just as aware of that death as someone who dies in the ICU after they get a heart transplant or a kidney transplant, he said.

In the case of kidney disease, the estimated 800,000 patients in the U.S. with end stage illness have two options: a transplant, which is unavailable to many, or dialysis, which is not a permanent solution, noted Megan Sykes, a Columbia University transplant immunobiologist who has pioneered methods for reducing cross-species organ rejection.

We have a temporary lifeline for people with end stage renal failure, but it really is temporary, said Sykes.

There are also reasons to believe xenotransplantation could work better in human trials than in monkeys, the panelists said. For one, monkeys used in research are smaller than adult humans, and are complicated to take care of. They are sensitive to therapies, and dont respond to certain immunosuppressant drugs that work well in humans. Plus, if organs could be more readily available than they currently are, fewer transplant recipients would be on their death bed, increasing the likelihood of a good outcome, Sykes said.

The transplants into the recently deceased patients at NYU offers a better proxy for live human transplants than the monkeys. Still, researchers cant monitor the success of such transplants long-term. So, we wouldnt be able to tell the patients exactly [the prognosis] unless we do the living cases and monitor for a year or two, said Insoo Hyun, director of research ethics at the Harvard Medical School Center for Bioethics.

The pig organs used in the recent transplants come from genetically edited pigs developed by Revivicor, intended to prevent organ rejection and make them safer for humans. Scientists have spent years fine-tuning and layering edits to the animal genes, but its still an open question how much genetic engineering is necessary, or if less is more, the panelists said. Montgomerys group used pig organs with one edit, while the Maryland team transplanted a pig organ with 10 edits.

Sykes wants the field to take a step back and assess how valuable or harmful each genetic tweak is. The Food and Drug Administration may be more receptive to organs with fewer edits.

Read the original post:
Xenotransplantation trials will require adjusting expectations, experts say - STAT

Read More...

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for … – KULR-TV

April 2nd, 2022 1:46 am

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc.(Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that data from its phenylketonuria (PKU) and homocystinuria (HCU) programs will be highlighted in two poster presentations at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting being held April 10-13, 2022 in Orlando, Florida.

Poster Presentations:

Abstract title (#70): Activity of SYNB1353, an Investigational Methionine-Consuming Synthetic Biotic Medicine, in an Acute Nonhuman Primate Model of Homocystinuria. Description: This presentation includes preclinical findings for SYNB1353, Synlogics drug candidate for HCU announced in November 2021, and shows significant blunting of plasma methionine and plasma homocysteine in response to an oral methionine load. Presenter: Mylene Perreault, PhD, SynlogicAbstract title (#74): Comparison of Phenylalanine Absorption in Healthy Volunteers and PKU Patients in the Synpheny-1 Study. Description: This presentation includes clinical data regarding the activity of SYNB1618 and SYNB1934, drug candidates in development for PKU, in metabolizing and reducing post-meal plasma levels of phenylalanine (Phe). Presenter: Marja Puurunen, MD, PhD, Synlogic

The poster presentations will be available in the Scientific Posters section of the Presentations and Publications page on the Synlogic website on April 11, 2022.

AboutSynlogic

Synlogicis a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogics pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogics proprietary, reproducible, target-specific drug design.Synlogicuses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases.Synlogicis also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogics approach to Synthetic Biotics with Ginkgos Codebase and Foundry services. For additional information visit http://www.synlogictx.com.

About SYNB1353

SYNB1353 is a novel orally administered, non-systemically absorbed drug candidate designed to consume methionine in the gastrointestinal tract thereby lowering homocysteine levels in patients with homocystinuria (HCU). HCU is an inherited disorder characterized by high levels of homocysteine and risks including thromboembolism, lens dislocation, skeletal abnormalities, developmental delay, and intellectual disability. Treatment options for HCU are currently limited due to efficacy and tolerability. SYNB1353 is currently in IND-enabling studies and was developed as part of a research collaboration withGinkgo Bioworks.Synlogicholds worldwide development and commercialization rights to SYNB1353, which is expected to begin clinical development and report Phase 1 data in healthy volunteers in H2 2022.

About SYNB1618 and SYNB1934

SYNB1618 and SYNB1934 are orally administered, non-systemically absorbed drug candidates being studied as potential treatments for phenylketonuria (PKU), a genetic disease caused by potentially neurotoxic levels of the amino acid phenylalanine (Phe). Treatment options for PKU are currently limited due to efficacy and safety, with an estimated 80% of US patients remaining in need of treatment, and many of those who are treated in need of additional Phe-lowering. Synlogic designed drug candidates to reduce levels of Phe in people with PKU using precision genetic engineering of the well-characterized probiotic E. coli Nissle. Findings to date support the potential for an efficacious, safe, convenient, and flexible treatment option for PKU, and SYNB1618 has received both Orphan Drug and Fast Track designations by the US Food and Drug Administration (FDA). Both drug candidates are being studied in the Phase 2 SynPheny-1 study, with initiation of the Phase 3 program expected to begin in H2 2022.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate toSynlogic,may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential ofSynlogic'sapproach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolismand inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approachSynlogicis taking to discover and develop novel therapeutics using synthetic biology; and the expected timing ofSynlogic'sclinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability ofSynlogicto protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" inSynlogic'sfilings with theSEC. The forward-looking statements contained in this press release reflectSynlogic'scurrent views with respect to future events.Synlogicanticipates that subsequent events and developments will cause its views to change. However, whileSynlogicmay elect to update these forward-looking statements in the future,Synlogicspecifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representingSynlogic'sview as of any date subsequent to the date hereof.

SOURCESynlogic, Inc.

Media Contact: Bill Berry Berry & Company Public Relations 212-253-8881; bberry@berrypr.com

Investor Contact: Andrew Funderburk Kendall Investor Relations 617-914-0008; afunderburk@kendallir.com

Original post:
Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV

Read More...

5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees – Crunchbase News

April 2nd, 2022 1:46 am

This is a new monthly column that will run down five interesting deals every month that may have flown under the radar.

This month, there were more than 2,000 funding deals given out to VC-backed companies globally, so its easy to miss some that are pretty intriguing.

Every month, well try to run down some that caught our attention here at Crunchbase News. These arent the largest rounds (we already do that) and they may not be from the biggest-named investors (we already do that too). Its just what we found interesting, quirky, notable or maybe a little off-the-wall, which brings us to .

Colossal Biosciences: The Dallas-based company closed a $60 million Series A led by Thomas Tull and At One Ventures. What caught our eye is that this isnt just a normal bioscience firm battling diseaserather its trying to solve de-extinction! Yes, like resurrection biology! (Which Hollywood has shown always turns out poorly, i.e. the whole Jurassic Park franchise).

The companywhich launched five months agois using genome engineering technologies to find a practical working model of de-extinction that will focus on the goal of the restoration and rewilding of functional woolly mammoths to the tundra. Colossal said bringing back mammoths would allow for a better understanding of evolutionary change in other species, and that genetic engineering applications also will help enhance food production and reduce environmental impact.

The other thing that piqued our interest about this were the investors. Thomas Tullof Legendary Entertainment (speaking of movies) and investment firm Tulco famegaming company Animoca Brands, Paris Hilton and several other investors from a variety of areas. A pretty eclectic bunchbut then again, maybe that fits in with the mission.

Grow your revenue with all-in-one prospecting solutions powered by the leader in private-company data.

Beewise: Speaking of saving species, lets talk about the bees. Insight Partners clearly wants to. The huge New York-based private equity/venture firm led an $80 million Series C into Israel-based Beewise, a robotics company that is focused on saving bees from climate change.

The companys proprietary robotic beehivethe Beehomehelps increase pollination capacity and honey production while also helping defend against threats like pesticides and pests. It also is thermally regulated and can even help feed the bees. The company said its tech can help reduce bee mortality by 80 percent, increase yields 50 percent, and eliminate approximately 90 percent of manual labor.

According to the EPA, more than 30 percent of honeybee colonies are disappearing each yeara rate that represents a risk to global food chains. Maybe thats why investors found this deal so sweet and have already poured more than $120 million into Beewise since it was founded in 2018.

Nautilus Labs: The New York-based maritime tech company closed a $34 million Series B this month. The companys tech is pretty cool, as it uses machine-learning to try to help ocean shippers lower emissions and fuel waste while also maximizing commercial returns. In its release on the raise, the company said shipping accounts for 3 percent of anthropogenic greenhouse gas emissionsGHGevery year. While that may not seem like a lot, if the industry does not change, its estimated that number will balloon to 17 percent by 2050.

While the maritime shipping industry and the tech around it is intriguing, the other reason the round made this list is who led the investmentM12 and the Microsoft Climate Innovation Fund. Thats right, Microsofts venture fund and its climate fund both made investmentssimultaneously. Thats the first time that has ever happened. Seems odd, but maybe Microsoft is just really interested in the maritime shipping space.

Pixxel: Yes, everybody seems to be launching satellites nowadays. But Palo Alto, California-based Pixxels earth-imaging tech puts a little different spin on it and is launching the first of its hyperspectral satellites as part of SpaceXs upcoming April Transporter-4 mission.

The company closed a $25 million Series A led by Radical Ventures this month, and will use the cash to advance its earth-imaging microsatellites, which the company says have 50x higher resolution than existing multispectral counterparts. Pixxels hyperspectral imaging allows it to collect data beyond just the visible light spectrum and across about 40x more wavelengths, which could include infrared and ultraviolet frequencies.

The fuller imaging would be able to do more thingsincluding monitor methane emissions or disease outbreaks across agricultural lands. Combining space, moving beyond the visible light spectrum, and helping solve real-world problems can get a company on this list.

Finless Foods: Admittedly, non-sea seafood is not brand new, but it still seemingly gets fewer headlines than faux meat and cheeseand certainly startups that focus strictly on it generally get less attention.

Emeryville, California-based Finless, which creates both cell-cultured and plant-based tuna, closed a $34 million Series B led by Hanwha Solutions this month. Its current focus is the bluefin tuna due to specific pressures on that industry and also its popularity.

Finless is part of the growing number of foodtech companies attracting investor interest as more start to worry about sustainability and food supply. According to Crunchbase numbers, investment into foodtecheverything from fake meat to vertical farmingreached a record $12.8 billion globally in 2021, double the amount of 2020.

Illustration: Dom Guzman

Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.

Original post:
5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News

Read More...

The Bay Area food tech industry is creating more than vegan burgers. Heres whats next – San Francisco Chronicle

April 2nd, 2022 1:46 am

One bite of the vegan ceviche at San Francisco restaurant West of Pecos is an eerie experience. The slippery cubes feel like raw tuna, with a similar briny, oceanic flavor. But they actually consist of bamboo, pea protein and algae, produced by a process that its creator, a local food tech startup, wont disclose.

The faux fish dish is a sign that the plant-based food industry is moving far beyond veggie burgers and soy nuggets. While the main players are focused on replacing products made from beef, chicken and pork, several new Bay Area companies are branching out. Theyve been quietly developing products, such as a surprisingly gamy lamb alternative, for years before finally hitting the market.

Analysts say the industry is at a turning point, and consumer demand for more variety is high. In 2021, retail sales of plant-based foods grew by 6.2% over the previous year, according to data released by the Plant Based Foods Association, the Good Food Institute and data technology company Spins. The year saw $1.4 billion in vegan meat sales the same as 2020, but 74% more than three years ago.

Meanwhile, investment in food tech is surging: The industrys deal value from mergers and acquisitions more than doubled from $6 billion in 2020 to $13.1 billion in 2021, according to a new report from Deloitte. Investors pooled more than $2 billion into plant-based proteins in 2021, said Heather Gates of Deloitte, with the industry expected to surpass $15 billion in value by 2026.

Fascinated by the food technology world, West of Pecos owner Tyler MacNiven said hed been searching for the first great vegan tuna when he heard about Current Foods, formerly known as Kuleana.

I was shocked at how convincing it was, he said. Its not the same (as tuna) but when its surrounded by accompanying flavors, the texture is so close.

The plant-based cerviche is served at West of Pecos in San Francisco. It pairs raw vegan tuna from Current Foods with corn, avocado and chipotle.

Current Foods CEO Jacek Prus said he entered the plant-based seafood realm because relatively few companies were tackling it. While its easy to find faux fish sticks and vegan crab cakes, whole cuts are rare. Prus said his company uses novel machinery and a secret process to turn bamboo fiber into a fillet.

West of Pecos became the first Bay Area restaurant to carry the tuna in November and is seeing rising sales every month, MacNiven said. Diners can expect the tuna-less tuna and a smoked salmon-esque product in more restaurants this year, Prus said, and the company is in the process of building a production facility in San Francisco.

Other plant-based meat options abound as well. The new vegan lamb from San Franciscos Black Sheep Foods, for example, is more widely available: tucked into wraps at Greek mini-chain Souvla, as a kebab topped with pickled persimmon at high-end Indian restaurant Rooh, and paired with labneh at a couple of Peninsula locations of Israeli spot Orens Hummus.

San Francisco mini chain Souvla was the first restaurant to carry plant-based lamb from Black Sheep Foods.

Black Sheep co-founder Sunny Kumar sees opportunity in wild game. After perfecting lamb it took 2 years to develop the first version he plans to tackle duck and wild boar.

To make the lamb, Black Sheep takes animal tallow from Tunis lamb, a New Zealand breed, through a biopsy to understand its fat and mouthfeel. The company determines which flavor compounds it needs to replicate, and then finds plants that produce those compounds as well. Black Sheep then sources those compounds from plants, ending up with a ground meat-like product bulked up with pea protein.

At first, Kumar said, his team put in all of the compounds before realizing they could actually improve the flavor of lamb. They could skip the pastoral, barnyard notes while still making sure you get the lamb burps, he said. Were not going to be shy.

Vegan lamb meatballs are served at Chezchez in San Francisco. The lamb comes from new food tech company Black Sheep Foods.

At hip San Francisco wine bar Chezchez, chef Timmy Malloy serves the lamb in meatball form with a spiced tomato sauce and garbanzo beans. He said he likes trying different vegan burgers. But at no point do I bite into them and think, This is cow, he said. Tasting Black Sheep, I went cross-eyed.

Perhaps the most stunning animal-free product being made in the Bay Area right now is the mozzarella from New Culture in San Leandro. While there are plenty of plant-based cheese outfits, theyre typically unable to produce the meltable, stretchy quality of real cheese. Thats because they lack casein, one of the proteins in cheese that co-founder Matt Gibson said allows milk to curdle.

New Cultures mozzarella melts because it contains real casein, though no cows are involved. Instead, the company uses microbes, genetic engineering and fermentation.

Microbes already produce proteins can we convince microbes to produce casein for us? said co-founder Inja Radman.

Pizza comes out of the oven with melted, animal-free mozzarella from New Culture.

The process called precision fermentation is an emerging sector of the food tech world. Its also used by Berkeleys Perfect Day, though that company is focused on whey, which can produce milk and cream cheese. Animal-free dairy is seeing rapid growth, according to Deloittes Gates, with $90 million invested in companies focused on vegan cheese in 2021.

New Cultures cheese is already virtually indistinguishable from real dairy. Raw, its bouncy and mildly sweet. In a 750-degree oven, it bubbles like lava in just one minute, sticking to a pizza wheel as its cut. The company is talking to San Francisco pizzerias, with plans to debut next year.

In Gibsons view, nut-based cheeses arent winning enough people over. He argued that the current array of plant-based foods is a stepping stone to better products. The only problem is these products wont reach the masses quickly, he said. It takes time to scale up; Black Sheep, for example, produces about 500 pounds in 90 minutes, which is already not enough to meet the demand from the many Indian, Middle Eastern and African restaurants that have been waiting for a lamb option, according to Kumar.

For now, however, there are still a lot of burgers. Theyll remain the industrys core, said Julie Emmett, the Plant Based Food Associations senior director of marketplace development. At the same time, theres the boredom factor, she said, with consumers wanting to see new options across every category.

August Schuchman, executive chef West of Pecos, sprinkles salt as he prepares the plant-based cerviche, using vegan tuna from Current Foods.

Despite promising sales data for the overall industry, not all players are finding continued success. Beyond Meat made headlines last fall when its stock fell by 48%. Some major chains are removing or looking into dropping the companys vegan meats, citing a niche market. Adam Parrish, a partner with Deloitte, chalked it up to larger food manufacturers entering the scene.

Some plant-based companies have done better. Some have had challenges, he said. Certainly, the competition is increasing.

And with those new competitors pitching themselves to Bay Area restaurants, the default vegan menu item may no longer be Impossible Burger in the not-too-distant future. MacNiven of West of Pecos said hes seeing a steady rise in diners scanning his menu specifically for plant-based options.

The tidal wave of plant-based customers, its coming. We feel it, he said. Everyone with a head start now is very wise.

Janelle Bitker is a San Francisco Chronicle staff writer. Email: janelle.bitker@sfchronicle.com Twitter: @janellebitker

See the original post here:
The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle

Read More...

Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A’s Heartland Challenge – University of Arkansas Newswire

April 2nd, 2022 1:46 am

Cari Humphry

Twelve graduate startup teams across North America will compete this spring in the third annual Heartland Challenge, a competition designed to simulate the process of raising venture capital for a high-growth enterprise.

"The Walton College is proud to host this outstanding international competition face to face in Bentonville this year," said Matt Waller, dean of the Walton College and Sam Walton Leadership Chair.

"We are grateful for the generous support of the Walton Family Charitable Support Foundation and other sponsors across our region, who share our commitment to bolstering entrepreneurship in the Heartland."

This year's cash prize pool has grown to more than $110,000, with the overall winner collecting $50,000. The second place team will receive $25,000; third place, $10,000; and fourth place, $5,000.

New for 2022 is an Investor Roundtable event, sponsored by Cadron Capital Partners, that will provide $3,000 awards to the winners of each of three roundtable events. This event, held alongside the main competition, will engage the student founders in informal discussions with active investors, simulating the experience of meeting in a restaurant or airport without the benefit of formal pitch decks or other materials. Additional special awards will be provided by sponsors Delta Solar, Atento Capital, Wright, Lindsey and Jennings, Natural Capital, John Chamberlin and Cannon Capital.

First and second place winners in the elevator pitch competition decided by an audience vote win $3,000 and $2,000, respectively.

The final round of the main competition will be livestreamed. To receive a link to view the event, please registerhere.

Past winners have included technology startups focused on the music industry and improving cancer detection. Having competed during years of the competition that were held virtually due to COVID-19 restrictions, the founders of both companies will be in attendance this year to share their post-competition experiences and join in the Startup Expo.

Aurign, a music publishing startup from Georgia State University, took home first place in 2020, securing $50,000 for their idea of using blockchain technology to securely file music-publishing documents.

NurLabs, a graduate student startup team from the University of California at Los Angeles, won the 2021 Heartland Challenge. The team, which developed a patent-pending, non-traditional, non-invasive liquid biopsy platform to detect cancer earlier, used its winnings to expand the size and scope of a lung cancer study.

NurLabs founder Sumita Jonak said, "The Heartland Challenge is a gem. I'm incredibly honored that NurLabs was recognized and validated by the no-nonsense investor panels as a viable medtech company. It gave me the confidence to push onward."

The 12 semi-finalist teams include:

About the U of A Office of Entrepreneurship and Innovation:The Office of Entrepreneurship and Innovation creates and curates innovation and entrepreneurship experiences for students across all disciplines. Through the Brewer Family Entrepreneurship Hub, McMillon Innovation Studio, Startup Village, and Greenhouse at the Bentonville Collaborative, OEI provides free workshops and programs including social and corporate innovation design teams, venture internships, competitions and startup coaching. A unit of the Sam M. Walton College of Business and Division of Economic Development, OEI also offers on-demand support for students who will be innovators within existing organizations and entrepreneurs who start something new.

See the original post:
Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire

Read More...

Should we test for differences in allergen content between varieties of crops and animal species? – Open Access Government

April 2nd, 2022 1:46 am

Food allergies are a serious, life-threatening condition. From a nut allergy to an aversion to kiwi, the consumption of food that triggers an inflammatory response in the human body has led to countless hospitalisations and deaths globally. The inflammation often stops air from reaching the lungs, creating a deadly window for a personto receive medical intervention.

So, have allergies been understand throughout US medical history? The shocking answer, given their extreme outcomes, is no. Did you know that allergies were only perceived as a serious medical condition in the USaround fifty to sixty years ago?

Then, by 1996, institutions and researchers began creating intensive rules and policies about how to protect those individuals from allergens. Self-identified food allergies, fuelled by a rise in social media, have led to a lot of confusion too.

However, as new foods are basically created via genetic engineering or introduction of new food sources in diets, what we know about allergens may change. As GMOs and Novel Foods are developed, how strict is the scrutiny over their potential allergens especially where they intersect into an existing product, used by thousands of people?

The new biotech proteins created by companies were required, under the newly built US laws around food, to be tested against existing allergens. They were then able to be identified as a risk or not, for the <2% of the population who have debilitating levels of food allergy.

Now, scientists are looking at how allergens interact with the varieties of crop that are made possible by GMO.

To find out more about this, read the words of Rick Goodman, an expert on this development at the Food Allergy Research and Resource Programme.

Editor's Recommended Articles

Originally posted here:
Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government

Read More...

Joris Deelen to present at the 9th Aging Research & Drug Discovery Meeting 2022 – EurekAlert

April 2nd, 2022 1:45 am

image:The ARDD Meeting 2022 will be hosted on August 29 - September 2, 2022 view more

Credit: Insilico Medicine Hong Kong Limited

March 31, 2022 -- Joris Deelen, Ph.D., will present the latest research on the topic Identification and functional characterisation of genetic variants linked to human longevity at the worlds largest annual Aging Research and Drug Discovery conference (9th ARDD). Dr. Joris Deelen is the Research Group Leader at the Max Planck Institute for Biology of Ageing.

"Previous research on the genetics of human longevity has shown that this trait is likely mainly determined by rare genetic variants. Therefore, the work in my group is currently focused on the functional characterisation of rare genetic variants identified in long-lived individuals. I recently obtained an ERC Starting Grant and a Longevity Impetus Grant to support this work." said Joris Deelen, Ph.D., Research Group Leader at the Max Planck Institute for Biology of Ageing.

Joris Deelen obtained his Ph.D. at the Leiden University Medical Center in the Netherlands in2014. In 2016, he joined the Max Planck Institute for Biology of Ageing as a postdoctoralresearcher where he was promoted to Research Group Leader in 2020. The work in his groupfocusses on the establishment of novel human aging studies in Cologne to determine theefficacy of previously identified biomarkers of aging in clinical studies. The main focus is onbiomarkers that have been identified in large-scale international collaborations of human studies using omics-based approaches, such as metabolomics.

The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at http://www.agingpharma.org. Please review the conference proceedings for 2019, 2020 and 2021https://www.aging-us.com/article/203859/text .

Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2022 conference is the best yet with top level speakers from around the globe. Im extremely excited to be able to meet them in person at the University of Copenhagen in late summer. said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place both offline and online, and it was a great success. I am particularly excited that being a part of the ARDD2022 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field. said Daniela Bakula, Ph.D., University of Copenhagen.

Many credible biopharmaceutical companies are now prioritized aging research for early-stage discovery or therapeutic pipeline development. It is only logical to prioritize therapeutic targets that are important in both aging and age-associated diseases. The patient benefits either way. The best place to learn about these targets is ARDD, which we organize for nine years in a row. This conference is now the largest in the field and is not to be missed, said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine and Deep Longevity.

Building on the success of the ARDD conferences, the organizers developed the Longevity Medicine course series with some of the courses offered free of charge at Longevity.Degree covered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.

About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.

About Scheibye-Knudsen Lab

In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

About Deep Longevity

Deep Longevity has been acquired by Edurance RP (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://longevity.ai/

About Endurance RP (SEHK:0575.HK)

Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. https://www.endurancerp.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the rest here:
Joris Deelen to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert

Read More...

Herd genetics begins with the bull | Agriculture | victoriaadvocate.com – Victoria Advocate

April 2nd, 2022 1:45 am

Texas is a huge beef state. In fact, it is one of the leading beef-producing states in the country. Right here in Victoria County alone, we have about 60,000 mother cows in production that add about $30 million to the agricultural income. All these mother cows require the right genetics to produce and achieve herd goals.

Many folks overlook the importance of bull genetics, and selection is crucial for herd genetic success. You cant tell everything you need to know about a bull just by looking at him. There are more tools than ever at your disposal in the beef industry. We will explore just a few in this article.

When looking for a new herd sire, many bull buyers get lost in all the data and acronyms that go along with selling purebred bulls today. In the past, most buyers evaluated bulls just by looking at them or by comparing them with other bulls in the pen. Today, bull breeders have a lot more data to offer buyers who want it, in addition to those who still like to just look.

Initially, that data included birth, weaning and yearling weight, adjusted for the sex of the calf; since males are heavier, and for the age of dam, due to the influence of milk production higher in older cows, lower in younger ones. Similarly, records on other traits such as carcass, fertility, longevity and docility were also collected.

About 60 years ago, it was realized that bulls and females could be evaluated for their actual genetic value in these traits. Each animal in the breed could be selected on their true genetic merit. These values were called Expected Progeny Differences or EPD. The EPD is calculated for each trait and for each animal in the breed. The EPD is reported in the units of the trait measured, for example pounds for weight. Each EPD also has an accuracy value that tells you how close the EPD really is to the animals true genetic value. It has made accurate selection to improve performance very easy.

Using DNA, beef cattle geneticists have been using genetic markers to improve the accuracy of the EPDs from young animals, especially young bulls, so that they can be selected earlier for traits of importance. They are called Genomic EPD or GE-EPD. Now, even young animals can be selected and used reliably to improve our genetics. This earlier selection also reduces bull development costs since the better bulls are identified earlier and more average and below average bulls are culled. Selecting younger bulls will improve selection success by reducing the amount of time between when a bull is selected for breeding and his calves actually hit the ground.

Select bulls using EPDs to improve traits that are of economic value to your operation. Select bulls that have a good health program and have passed a breeding soundness examination.

For more information, please call the Victoria County Extension Office at (361) 575-4581.

Matt Bochat is a County Extension Agent Ag/Natural Resources Victoria County Texas A&M Agrilife Extension.

Read the original post:
Herd genetics begins with the bull | Agriculture | victoriaadvocate.com - Victoria Advocate

Read More...

Page 185«..1020..184185186187..190200..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick